318 related articles for article (PubMed ID: 30217489)
1. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.
Ferrer L; Giaj Levra M; Brevet M; Antoine M; Mazieres J; Rossi G; Chiari R; Westeel V; Poudenx M; Letreut J; Gervais R; Osman G; Girard N; Toffart AC; Novello S; Moro-Sibilot D
J Thorac Oncol; 2019 Jan; 14(1):130-134. PubMed ID: 30217489
[TBL] [Abstract][Full Text] [Related]
2. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
3. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From
Zhang B; Lewis W; Stewart CA; Morris BB; Solis LM; Serrano A; Xi Y; Wang Q; Lopez ER; Concannon K; Heeke S; Tang X; Raso G; Cardnell RJ; Vokes N; Blumenschein G; Elamin Y; Fosella F; Tsao A; Skoulidis F; Hume CB; Sasak K; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Tran H; Zhang J; Gibbons D; Vaporciyan A; Wang J; Park K; Heymach JV; Byers LA; Gay CM; Le X
JTO Clin Res Rep; 2024 Feb; 5(2):100623. PubMed ID: 38357092
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
8. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.
Yang H; Liu L; Zhou C; Xiong Y; Hu Y; Yang N; Qu J
Medicine (Baltimore); 2019 Mar; 98(12):e14893. PubMed ID: 30896637
[TBL] [Abstract][Full Text] [Related]
10. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
11. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
Liu Y
Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
[TBL] [Abstract][Full Text] [Related]
12. Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC.
Liang X; Lin A; Wang Q; Zhang J; Luo P
Biomed Pharmacother; 2022 May; 149():112909. PubMed ID: 36068773
[TBL] [Abstract][Full Text] [Related]
13. Small cell lung cancer transformation: From pathogenesis to treatment.
Yin X; Li Y; Wang H; Jia T; Wang E; Luo Y; Wei Y; Qin Z; Ma X
Semin Cancer Biol; 2022 Nov; 86(Pt 2):595-606. PubMed ID: 35276343
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.
Jing M; He X; Cai CZ; Ma QZ; Li K; Zhang BX; Yin Y; Shi MS; Wang YS
Biochem Biophys Res Commun; 2023 Nov; 681():218-224. PubMed ID: 37783120
[TBL] [Abstract][Full Text] [Related]
16. Expression of
Zhang SL; Zhang CY; Chen YQ; Li YF; Xie Z; Zhang XC; Zhou Q; Zhong WZ; Huang J; Sun H; Zheng MY; Xiao FM; Yan HH; Lu DX; Lv ZY; Wu YL; Chen HJ; Yang JJ
J Thorac Dis; 2023 Sep; 15(9):4620-4635. PubMed ID: 37868836
[TBL] [Abstract][Full Text] [Related]
17. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
Zeng J; Ding X; Ding J; Wang X
Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
[TBL] [Abstract][Full Text] [Related]
18. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
[TBL] [Abstract][Full Text] [Related]
19. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S
Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401
[TBL] [Abstract][Full Text] [Related]
20. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
